Observational Study of MRD Testing in Triple-Negative Breast Cancer
This observational study is looking at how well a special blood test, called ctDNA-based MRD (circulating tumor DNA - minimal residual disease) testing, can predict if treatment for triple-negative breast cancer (TNBC) has been successful. Researchers want to see if detecting tiny amounts of cancer DNA in your blood after chemotherapy (neoadjuvant chemotherapy or NAC) matches up with how much cancer is left in your breast tissue. You could join if you are a woman, 18 or older, have early-stage TNBC, and are scheduled to receive NAC. The study aims to enroll 422 participants. The main goal is to understand the connection between MRD and a complete response to treatment, which could help improve future care for patients with TNBC.
- Study design
- This is an observational study, meaning researchers will watch and collect information without giving any specific treatments. It aims to include 422 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be evaluated through study completion, which is an average of 6 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
CtDNA Based MRD Testing for NAC Monitoring in TNBC
At a glance
Conditions
Where it's being run
14 sites across 13 statesStudy leadership
- Pavani Chalasani · PRINCIPAL_INVESTIGATOR · George Washington University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Evaluate the correlation of MRD to pCR after NAC in TNBCthrough study completion, an average of 6 months
Evaluate the correlation of MRD detection by NeXT Personal CTA to pathological Complete Response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). The pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy.